Baugh & Associates LLC Reduces Holdings in Kenvue Inc. (NYSE:KVUE)

Baugh & Associates LLC trimmed its position in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,770 shares of the company’s stock after selling 1,337 shares during the quarter. Baugh & Associates LLC’s holdings in Kenvue were worth $1,674,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. LPL Financial LLC purchased a new stake in shares of Kenvue during the second quarter valued at $526,000. Envestnet Asset Management Inc. purchased a new stake in shares of Kenvue during the second quarter worth about $1,387,000. TD Asset Management Inc purchased a new stake in shares of Kenvue during the second quarter worth about $12,634,000. Cetera Investment Advisers purchased a new stake in shares of Kenvue during the second quarter worth about $416,000. Finally, Citigroup Inc. purchased a new stake in Kenvue in the second quarter valued at approximately $57,000. 11.33% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 0.0 %

Shares of KVUE opened at $20.21 on Wednesday. The stock has a 50-day simple moving average of $20.08 and a 200-day simple moving average of $20.29. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUEGet Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s revenue was down 2.7% on a year-over-year basis. As a group, equities analysts forecast that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend was Tuesday, February 13th.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. JPMorgan Chase & Co. decreased their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Finally, UBS Group lifted their price target on Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, December 19th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.42.

Check Out Our Latest Research Report on KVUE

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.

Read More

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.